Notice of Special Interest (NOSI): Supporting Data Sciences in the IDeA States through the Centers of Biomedical Research Excellence (COBRE) Phase I Program
Notice Number:
NOT-GM-21-062

Key Dates

Release Date:

August 26, 2021

First Available Due Date:
January 27, 2022
Expiration Date:
January 28, 2022

Related Announcements

PAR-19-313 - Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 Clinical Trial Optional)

Issued by

National Institute of General Medical Sciences (NIGMS)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Data Science Strategy (ODSS)

Purpose

The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the National Institutes of Health’s interest in supporting data sciences research in Institutional Development Award (IDeA)-eligible states through PAR-19-313 "Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 Clinical Trial Optional)."

Research Objectives

The complexity and volume of basic, translational, and clinical research data continue to increase rapidly. To take full advantage of these data, it is critically important to foster innovative approaches to work with large research datasets and to develop a talented and diverse data science workforce. The NIH Office of Data Science Strategy (ODSS), which leads the implementation of the NIH Strategic Plan for Data Science through collaborations with NIH institutes, centers, and offices, intends to support one COBRE award to advance data science in IDeA states through this funding opportunity announcement, in addition to NIGMS' funding of meritorious COBRE phase I applications aimed at advancing data science.

Applications aimed at building research capacity in a broad range of data science areas including machine learning, deep learning, artificial intelligence and virtual reality technologies, are welcome. Applications that will build capacity in multiple areas of data science, rather than a small number of narrowly focused areas, will be a priority for funding. The proposed center must address one or more of the five overarching goals of the NIH Strategic Plan for Data Science and adhere to the principles of making biomedical research data findable, accessible, interoperable, and reusable (FAIR).

Application and Submission Information

This Notice applies to the January 27, 2022 due date.

Applications for this initiative must be submitted to and be in full compliance with the following funding opportunity announcement (FOA):

  • PAR-19-313 - Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 Clinical Trial Optional).

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

  • For funding consideration, applicants must include “NOT-GM-21-062” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will be withdrawn from consideration for this initiative.

Inquiries

Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:

Lakshmi Kumar Matukumalli, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Email: lakshmi.matukumalli@nih.gov

Vivian Ota Wang, Ph.D.
NIH Office of Data Science Strategy (ODSS)
Email: vivian.otawang@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices